Peter Miller, Optinose CEO
June 13, 2022 10:45 AM EDT
R&D

Look­ing to ex­pand nasal spray in­di­ca­tion, Opti­nose se­cures sec­ond PhI­II win

Lei Lei Wu

News Reporter

Hav­ing got­ten ap­proval for its nasal polyps treat­ment four and a half years ago, Opti­nose is look­ing to ex­pand in­to a pa­tient pop­u­la­tion that’s 10 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times